We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adma Biologics Inc | NASDAQ:ADMA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 1.04% | 6.81 | 1.50 | 7.30 | 6.81 | 6.65 | 6.78 | 2,985,669 | 05:00:01 |
ADMA BIOLOGICS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-36728
|
56-2590442
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
465 State Route 17, Ramsey, New Jersey
|
07446
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
ADMA
|
Nasdaq Global Market
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders
|
1. |
The election of two (2) Class III directors to serve until the Company’s 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their successors shall have been duly elected and qualified;
|
2. |
The approval of the 2022 Equity Plan;
|
3. |
The approval of the compensation of the Company’s named executive officers, on an advisory basis; and
|
4. |
The ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
Nominees
|
For
|
Withheld
|
Broker Non-Votes
|
|||
Jerrold B. Grossman D.P.S.
|
97,657,992
|
3,694,868
|
38,956,434
|
|||
Lawrence P. Guiheen
|
96,486,906
|
4,865,954
|
38,956,434
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
94,008,724
|
6,146,254
|
1,197,882
|
38,956,434
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
94,938,796
|
5,332,324
|
1,081,740
|
38,956,434
|
For
|
Against
|
Abstain
|
||
138,610,710
|
1,517,616
|
180,968
|
Item 9.01
|
Exhibits.
|
Exhibit No.
|
Description
|
ADMA Biologics, Inc. 2022 Equity Compensation Plan
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
June 21, 2022
|
ADMA Biologics, Inc.
|
||
By:
|
/s/ Brian Lenz
|
||
Name:
|
Brian Lenz
|
||
Title:
|
Executive Vice President and Chief Financial Officer
|
1 Year Adma Biologics Chart |
1 Month Adma Biologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions